Asbestos is regarded as a hazardous substance because it causes cancer. This post explains the medical and epidemiological foundations behind that: which diseases asbestos causes and how they differ (Section 1), why what counts for the risk is not the mere presence of fibres but the cumulative dose over time (Section 2), and why "white asbestos" and "blue asbestos" are not equally dangerous (Section 3). This is the general, supra-regional part. The Austrian findings and the mesothelioma clusters are covered by a second part, the question of undercounting by the article The occupational-disease gap; the concrete case is documented on the Burgenland page. Every statement is backed by primary sources; the full citations are at the end.
Mesothelioma and lung cancer: two diseases, one substance
Asbestos causes several diseases. At the centre of this post are two cancers that are often confused although they differ fundamentally: mesothelioma and lung cancer. Beyond these, asbestos also causes non-malignant conditions, above all asbestosis, a scarring (fibrosis) of the lung tissue after high exposure, and benign changes of the pleura (pleural plaques); the evidence is also regarded as sufficient that asbestos causes cancer of the larynx and the ovary (Wolff et al. 2015). These further conditions are only named here, not treated in depth.
Mesothelioma is a tumour of the mesothelium, the thin cell layer that lines the chest and abdominal cavities. It arises mostly at the pleura, the lining of the chest, and more rarely at the peritoneum, the lining of the abdomen (Robinson et al. 2005); the share of peritoneal mesotheliomas varies considerably between occupationally exposed groups and rises with the level of exposure (IARC 2012). It is the signature disease of asbestos. Few common cancers have so direct a causal relation to a defined carcinogen as mesothelioma has to asbestos, a closer one even than lung cancer to tobacco smoke (Robinson et al. 2005). According to Robinson et al. (2005), it was recognised as an asbestos-related disease in the 1950s in South Africa's Cape Province; the corresponding case series by Wagner et al. (1960) comprised 33 histologically confirmed cases of diffuse pleural mesothelioma, all but one with probable exposure to crocidolite, in the majority in the local Asbestos Hills. Individual mesotheliomas in asbestos workers had been reported before (as cited in Wagner et al. 1960). Robinson et al. (2005) called mesothelioma a universally fatal disease with a median survival of 9 to 12 months; no chemotherapy had proven curative. In a phase III trial in pleural mesothelioma, median survival under pemetrexed and cisplatin was 12.1 months against 9.3 months under cisplatin alone, at a response rate of 41 % (Vogelzang et al. 2003). As first-line treatment of unresectable pleural mesothelioma, the immunotherapy of nivolumab and ipilimumab reached a median survival of 18.1 months in the CheckMate 743 trial against 14.1 months under standard chemotherapy with platinum and pemetrexed; after two years, 41 % against 27 % of patients were alive (Baas et al. 2021). Unlike lung cancer, mesothelioma does not depend on smoking, presumably because the carcinogens in tobacco smoke do not reach the mesothelium (Robinson et al. 2005).
Asbestos-related lung cancer, by contrast, is an ordinary bronchial carcinoma: all four major histological types can be related to asbestos, and the location of the tumour in the lung is of no importance for attribution (Wolff et al. 2015). Lung cancer is multifactorial: the main cause is smoking (Hodgson and Darnton 2000), and asbestos is one of several possible additional causes. The increase in risk from asbestos is dose-dependent, and asbestos and smoking reinforce one another. Exactly how this interplay is to be described is not conclusively settled (see the fold-out below). For attributing a particular lung cancer to asbestos exposure, the Helsinki criteria have become established: as a guideline value, a cumulative exposure of 25 fibre-years doubles the lung-cancer risk (Wolff et al. 2015).
The difference is thus twofold. First, location and specificity: mesothelioma arises in the mesothelium and in the great majority of cases is due to asbestos exposure (Wolff et al. 2015), whereas lung cancer arises in the lung tissue and has many causes, of which asbestos is only one. Second, and less well known, the magnitude: in public perception mesothelioma stands in the foreground, yet asbestos causes more lung-cancer deaths than mesothelioma deaths overall. From the follow-up of 55 cohorts of asbestos-exposed workers, McCormack et al. (2012) estimated the ratio of additional asbestos-related lung-cancer deaths to mesothelioma deaths, by fibre type, at about 0.7 for crocidolite, about 4 for amosite and, with great estimation uncertainty, about 6 for chrysotile; across all fibre types except crocidolite, asbestos claims at least twice as many lives through lung cancer as through mesothelioma (McCormack et al. 2012). The high ratio for chrysotile follows from the small number of chrysotile-related mesotheliomas in the denominator, not from a particularly high lung-cancer potency of chrysotile. Mesothelioma is thus the more specific consequence, lung cancer, except under crocidolite exposure, the quantitatively weightier one.
For experts (or the expert-curious): how asbestos transforms the mesothelium, and why the latency is so long
How a mineral fibre triggers cancer in the mesothelium cannot be traced to a single mechanism. Robinson et al. (2005) name four plausible routes that do not exclude one another. First, mechanical irritation: long, thin fibres penetrate deep into the lung, can pierce the lung epithelium and damage the mesothelial surface in repeated cycles of injury, repair and local inflammation, which can lead to scarring (plaques) or to cancer. Second, disturbance of mitosis: fibres can sever or pierce the mitotic spindle and so produce aneuploidy and further chromosomal damage that characterise mesothelioma. Third, the formation of reactive, iron-mediated oxygen species that cause DNA damage and strand breaks. Fourth, persistent kinase-mediated signalling, for instance the activation of the mitogen-activated protein kinases and the extracellular signal-regulated kinases 1 and 2 (Robinson et al. 2005).
At the molecular-pathological level, mesothelioma is unusual. What dominates is not the loss of the tumour suppressors p53 or Rb that is common in many tumours, but the loss of P16INK4A, P14ARF and NF2 (Robinson et al. 2005). This specific signature of tumour-suppressor loss is regarded as characteristic of mesothelioma development.
The latency, that is, the time from first exposure to disease, is extraordinarily long. In the first roughly 10 to 15 years after first exposure the risk is practically zero; thereafter it keeps rising for life, with typical latencies of more than 30 years (Robinson et al. 2005). A prospective British cohort determined a partly shorter median latency of 22.8 years (95 % confidence interval 16.0 to 27.2 years), in women about 29 % longer than in men (Frost 2013). The less obvious conclusion: because mesothelioma is unrelated to smoking, because the risk does not recede after exposure and rises over decades, the disease is an almost pure image of past asbestos exposure.
Taking Burgenland as an example: because decades lie between exposure and disease, a present-day burden from asbestos-bearing rock will only show up as possible illness in the distant future, and conversely cases observed today reflect the exposures of earlier decades.
For experts (or the expert-curious): the dose-response in lung cancer, the 25-fibre-year threshold, and the dispute over the smoking synergy
Unlike mesothelioma, a single lung cancer cannot be identified as asbestos-related from the tissue. Attribution is therefore made via the exposure. The Helsinki criteria define, as a guideline value, that a cumulative exposure of 25 fibre-years doubles the lung-cancer risk (Wolff et al. 2015); this measure, the fibre-year, is the subject of the following section.
Asbestos and smoking act over-additively together, that is, more strongly than the mere sum of their individual effects. Exactly how is disputed. An analysis of 23 studies on the joint effect found no general departure from the multiplicative model (Lee 2001), in which the relative risks multiply. A more recent meta-analysis of 17 studies, by contrast, draws an over-additive but not strictly multiplicative picture: in the ten case-control studies the additive synergy index was 1.44 (95 % confidence interval 1.26 to 1.77), the multiplicative index 0.91 (0.63 to 1.30); in the seven cohort studies the values were 1.11 and 0.51 respectively (Ngamwong et al. 2015). What remains undisputed is both: the combination is markedly more dangerous than either factor alone, and its exact mathematical form is not conclusively settled.
The quantitative burden thus shifts toward lung cancer. In a population with 2 mesothelioma deaths per 1000 deaths at ages 40 to 84, for instance US men, McCormack et al. (2012) estimated the share of all lung-cancer deaths attributable to mixed asbestos, the population attributable fraction, at 4.0 %. For chrysotile, the asbestos most used worldwide today, the number of asbestos-related lung cancers can, however, be estimated only uncertainly from the few mesothelioma deaths (McCormack et al. 2012).
Taking Burgenland as an example: whether and how strongly an environmental burden counts is a question of the cumulative dose and not of the mere presence of individual fibres. The measure for it, the fibre-year, and the question of what low background burdens mean, are the subject of the following section.
Acute and background: why the dose matters, not the single fibre
Asbestos exposure occurs at very different levels. At one end stands the acute, high exposure at the workplace, for instance of insulation workers, miners or remediation workers who handled dense fibre dust over years. At the other end stands the low background burden of the environment: asbestos is ubiquitous in industrialised areas, and almost everyone who lives there carries asbestos fibres in the lung (Robinson et al. 2005). The decisive question is therefore rarely whether fibres are present at all, but how many were inhaled over what time.
To make this cumulative dose measurable, occupational medicine uses the fibre-year. A fibre-year is the product of fibre concentration and exposure duration: it corresponds to the exposure to one million fibres per cubic metre (10⁶ F/m³, that is one fibre per cubic centimetre) over a working year, namely eight hours on 240 working days (DGUV 2013). The fibre-year is thus the asbestos counterpart to the "pack-year" in smoking: not the snapshot of a concentration, but the burden summed over time.
In the German occupational-disease framework a particular cumulative dose serves as a threshold. A lung cancer is recognised as occupational disease No. 4104, among other conditions, when exposure to a cumulative asbestos-fibre-dust dose of at least 25 fibre-years is demonstrated (DGUV 2013). This value is a doubling dose: at 25 fibre-years the lung-cancer risk is doubled (Wolff et al. 2015). The results of a German case-control study are compatible with a doubling of the lung-cancer risk at 25 fibre-years (Pohlabeln et al. 2002). How the Austrian recognition system is built, and why only part of the illnesses are counted as an occupational disease, is covered by the article The occupational-disease gap.
Below this recognition threshold the risk does not, however, vanish; according to the Helsinki criteria, asbestos can contribute to causing disease even at lower exposures (Wolff et al. 2015). In a cohort of chrysotile textile workers, the exposure-response relationship for lung cancer was approximately linear, with no indication of a threshold value (Stayner et al. 1997). The EU explicitly treats asbestos as a carcinogen without a threshold, for which no limit value can be identified below which exposure would be harmless; an occupational limit value can instead be set via an exposure-risk relationship that takes into account an acceptable level of additional risk (Directive (EU) 2023/2668). The 25 fibre-years are accordingly a doubling dose for recognition, not a value below which asbestos would be harmless.
For experts (or the expert-curious): the fibre-year, occupational disease BK 4104, and the limits of a high-dose measure
The fibre-year is defined as a product, formally 25 fibre-years = 25 · 10⁶ [(fibres/m³) · years] (DGUV 2013). A cumulative dose of one fibre-year can therefore be reached in various ways, for instance through one working year at 10⁶ F/m³ or through ten working years at 10⁵ F/m³; what is decisive is solely the product of concentration and duration. The occupational fibre-year is thereby normalised to eight hours on 240 days; a continuous environmental burden over a full calendar year yields, at the same concentration, about four and a half times as much, which must be kept in mind when transferring to local-resident exposures. Only respirable fibres that have been released from the material are counted: by the recognised criteria, fibres with a length over 5 µm, a diameter under 3 µm and a ratio of length to diameter greater than 3:1.
The 25-fibre-year threshold was introduced in 1992 by the Second Ordinance amending the German Occupational Diseases Ordinance; it was based on studies from the asbestos textile, asbestos cement and insulation sectors, according to which doses of 20 to 24 fibre-years doubled lung-cancer mortality (DGUV 2013). A later test on German data is the two-phase case-control study of Pohlabeln et al. (2002): the smoking-adjusted odds ratios for the fibre-year categories under 1, 1 to under 10 and over 10 were 0.86, 1.33 and 1.94 in the two-phase model; only the value for the highest category reached statistical significance. The result is compatible with a doubling at 25 fibre-years (Pohlabeln et al. 2002).
The exposure-response analysis of a cohort of chrysotile textile workers in South Carolina found no threshold: for lung cancer the relationship proved approximately linear, for asbestosis non-linear, and the models fitted best when the threshold parameter was set to zero (Stayner et al. 1997). The authors themselves point out that their observations rest on comparatively high exposures and that their lung-cancer risks are higher than in other chrysotile-exposed groups. Hodgson and Darnton (2000) regard the experience of this cohort as untypically high and consider a threshold for chrysotile-related lung cancer at low cumulative exposures arguable. For mesothelioma, by contrast, Hodgson and Darnton see no good case for assuming any threshold, and in their assessment any threshold for lung cancer from amphibole asbestos would be very low (Hodgson and Darnton 2000).
In legal terms, Austria applies to asbestos at the workplace a TRK value (technical guidance concentration) of 10,000 fibres per cubic metre, and of 2,000 fibres per cubic metre from 21 December 2029 (GKV 2025, Annex I). A TRK value states the concentration that can be achieved by the state of the art and is to be undercut as far as possible (§ 45(2) and (4) ASchG). The German TRGS 910, as state of the art, assigns an acceptance risk and a tolerance risk each a substance-specific air concentration, for asbestos 10,000 and 100,000 fibres per cubic metre (TRGS 910).
The less obvious conclusion concerns the reach of the measure. The fibre-year and the dose-response curves underlying it come from occupational cohorts with high exposure. The transfer to very low, long-term environmental burdens is subject to considerable uncertainty, because this dose range is barely covered by the underlying studies. The measure describes the occupational world precisely; at its lower edge it becomes extrapolation.
Taking Burgenland as an example: for local residents the question is a low, chronic environmental burden, a dose range far below the occupational cohorts. It is not mere background everywhere, though: according to the Land's data sheet, fibre levels in outdoor air were partly above the background levels to be expected everywhere, and in its assessment values above them give reason to act for precautionary health protection (Land Burgenland 2026). The measurements are documented on the Burgenland page.
White and blue: why not all asbestos is equally dangerous
"Asbestos" is not a single substance but a collective term for fibrous minerals from two groups. The serpentine group provides, in chrysotile, the "white asbestos", the most commonly occurring and most used asbestos type worldwide (IARC 2012; Stayner et al. 1997). The amphibole group comprises crocidolite ("blue asbestos") and amosite ("brown asbestos"), which besides chrysotile were the principal commercial types (Hodgson and Darnton 2000), as well as tremolite, actinolite and anthophyllite asbestos; anthophyllite asbestos was mined in Finland, for instance (IARC 2012). All six asbestos types are regarded as carcinogenic to humans and are classified by the International Agency for Research on Cancer (IARC) in Group 1 (Gualtieri et al. 2018; IARC 2012). In their potency, however, they differ considerably.
For mesothelioma the amphiboles are far more potent than chrysotile. In an evaluation of occupational cohorts Hodgson and Darnton (2000) estimated the relative mesothelioma potency of chrysotile, amosite and crocidolite at a ratio of about 1:100:500; these potency estimates are, however, subject to considerable uncertainty. For lung cancer the potency difference between chrysotile and the amphiboles is, by contrast, markedly smaller, lying roughly in the range of 1:10 to 1:50, yet remaining substantial (Hodgson and Darnton 2000).
Older than these estimates is the "amphibole hypothesis": the assumption that the mesotheliomas observed in chrysotile-exposed workers could be explained by concurrent exposure to amphiboles and that chrysotile is less carcinogenic. Stayner et al. (1996) examined it critically. Their finding: mechanistic and lung-burden studies do not convincingly support the hypothesis; chrysotile is associated with an increased risk of lung cancer and mesothelioma; it may be less potent for inducing mesotheliomas than some amphiboles, but for a lower lung-cancer risk there is little evidence. Their conclusion: it is prudent to treat chrysotile with nearly the same concern as the amphibole forms (Stayner et al. 1996). Lower mesothelioma potency therefore does not mean harmlessness. For lung cancer, however, the estimate of Hodgson and Darnton and the finding of Stayner et al. are in tension: Hodgson and Darnton (2000) call their own conclusion there less clear-cut, because the chrysotile cohorts do not give a consistent picture; the experience of the textile workers in Carolina differs clearly from that of the Quebec miners and looks untypically high to them.
IARC (2012) names biopersistence, that is, how long a fibre remains in the lung, as one of the reasons for a possible difference in carcinogenicity; it is higher for the amphiboles. At the same time IARC notes that the lower biopersistence of chrysotile does not necessarily imply a lower potency for lung cancer. One component of biopersistence is biodurability, the resistance to dissolution. Gualtieri et al. (2018) determined it comparatively in dissolution experiments in Gamble solution, a simulated lung fluid, at pH 4 and body temperature; this acidic medium is meant to reproduce the environment of a fibre that a scavenger cell (macrophage) has taken up and enclosed in its phagolysosome. For a 0.25 µm thick fibre they calculated a dissolution time of 94 to 177 days for chrysotile, against 49 to 245 years for amphibole fibres. Fibres can also lie outside the cells, at a neutral pH of 7.4; there, according to the authors, their dissolution is too slow, even for chrysotile, for an accurate kinetic study, and experiments at neutral pH were therefore not carried out. The longer a fibre remains in the lower respiratory tract, the greater the probability that it causes damage (Gualtieri et al. 2018). We cover the geochemical mechanics behind this, why chrysotile in particular dissolves so much faster, in the geology article.
The amphiboles also matter for environmental exposures: tremolite asbestos can occur in chrysotile deposits, whose fibres lie as veins in serpentine rock (IARC 2012). That an environmental exposure to tremolite, that is, outside the workplace, can trigger mesotheliomas is well documented: in Metsovo in Greece, where a whitewash consisting predominantly of asbestiform tremolite was used (Langer et al. 1987), and in New Caledonia, where a population-based case-control study found, for the use of a tremolite-bearing whitewash, a mesothelioma risk with an odds ratio of 40.9 (95 % confidence interval 5.15 to 325) (Luce et al. 2000). The wide confidence interval reflects the small number of cases; the direction of the finding is, however, unambiguous. A serpentinite that carries, alongside chrysotile, also tremolite or actinolite is therefore more than "just white asbestos".
For experts (or the expert-curious): the evidence behind the amphibole hypothesis
Two studies after the review by Stayner et al. (1996) partly support the hypothesis. Roggli et al. (2002) examined the fibre content of the lung in 312 mesothelioma cases, mostly after contact with asbestos-containing products: tremolite was found in 166 cases (53 %) and lay above background level in 81 cases (26 %), chrysotile by contrast in only 32 cases (10 %); Roggli et al. trace this tremolite partly to accompanying chrysotile, partly to talc, and regard it as the likely cause in some of the patients. In the Quebec chrysotile mining districts, the risks of mesothelioma and lung cancer were raised in the centrally located mines, whose tremolite contamination was about four times that of the peripheral mines (McDonald and McDonald 1997). Both suggest that tremolite contributes to the mesotheliomas observed under "chrysotile exposure".
The conclusion from this is, however, not that chrysotile would be harmless. Already before these studies, Stayner et al. (1996) recorded that the mechanistic and lung-burden evidence does not convincingly support the amphibole hypothesis, that chrysotile is associated with both lung cancer and mesothelioma, and that for a lower lung-cancer risk of chrysotile there is little evidence. Lower mesothelioma potency and harmlessness are two different things.
Taking Burgenland as an example: the southern-Burgenland material carries, by our own findings as well as others', not only chrysotile but also the amphiboles tremolite and actinolite (see the Burgenland page). The potency scale of Hodgson and Darnton (2000) covers only chrysotile, amosite and crocidolite and contains no estimate of its own for these two amphiboles; it is documented, however, that tremolite can cause mesothelioma outside the workplace as well (Langer et al. 1987; Luce et al. 2000).
For experts (or the expert-curious): biopersistence, why chrysotile dissolves and amphibole remains
Biopersistence is one of the key parameters of fibre toxicity: the longer a fibre withstands the physiological clearance and dissolution processes, the longer it can act in the tissue (Gualtieri et al. 2018). In the same dissolution experiment the amphibole fibres and the fibrous erionite showed, even after 9 to 12 months, only slight signs of dissolution, whereas chrysotile rapidly turns into a silica-rich, amorphous pseudomorph that initially preserves the fibre shape (Gualtieri et al. 2018). In chrysotile the magnesium octahedral layer is leached first, but the lifetime of the fibre is controlled by the slower dissolution of the silica layer; in amphiboles such as tremolite, cations are replaced at the surface without a major change in the silicate framework (Gualtieri et al. 2018). We cover the crystal chemistry behind this in detail in the geology article.
Taking Burgenland as an example: the amphibole asbestos detected in the Burgenland material is, by this logic, the more durable and thus the health-wise more critical share; whether asbestiform amphibole fibres can be distinguished analytically from cleavage fragments of the same geometry is covered on the standards page.
Sources
- ASchG: ArbeitnehmerInnenschutzgesetz, BGBl. Nr. 450/1994 in der geltenden Fassung, § 45. Rechtsinformationssystem des Bundes (RIS). ris.bka.gv.at
- Baas, P., Scherpereel, A., Nowak, A. K. et al. (2021): First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. The Lancet 397(10272):375–386. doi.org/10.1016/S0140-6736(20)32714-8
- DGUV (2013): BK-Report 1/2013 „Faserjahre". Deutsche Gesetzliche Unfallversicherung, Institut für Arbeitsschutz (IFA), 5. Auflage. ISBN 978-3-86423-042-4.
- Directive (EU) 2023/2668: Richtlinie (EU) 2023/2668 des Europäischen Parlaments und des Rates vom 22. November 2023 zur Änderung der Richtlinie 2009/148/EG über den Schutz der Arbeitnehmer gegen Gefährdung durch Asbest am Arbeitsplatz. Amtsblatt der Europäischen Union, Serie L, 2023/2668, 30.11.2023. eur-lex.europa.eu
- Frost, G. (2013): The latency period of mesothelioma among a cohort of British asbestos workers (1978–2005). British Journal of Cancer 109(7):1965–1973. doi.org/10.1038/bjc.2013.514
- GKV 2025: Grenzwerteverordnung 2025, BGBl. II Nr. 253/2001 in der Fassung BGBl. II Nr. 339/2025, Anhang I/2025 (Stoffliste). Rechtsinformationssystem des Bundes (RIS). ris.bka.gv.at
- Gualtieri, A. F., Pollastri, S., Bursi Gandolfi, N. & Gualtieri, M. L. (2018): In vitro acellular dissolution of mineral fibres: a comparative study. Scientific Reports 8:7071. doi.org/10.1038/s41598-018-25531-4
- Hodgson, J. T. & Darnton, A. (2000): The quantitative risks of mesothelioma and lung cancer in relation to asbestos exposure. Annals of Occupational Hygiene 44(8):565–601. doi.org/10.1093/annhyg/44.8.565
- IARC (2012): Asbestos (Chrysotile, Amosite, Crocidolite, Tremolite, Actinolite and Anthophyllite). In: Arsenic, Metals, Fibres and Dusts. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, Vol. 100C. International Agency for Research on Cancer, Lyon. ncbi.nlm.nih.gov/books/NBK304374
- Land Burgenland (2026): Taskforce Vorsorgeabklärung Luftqualität, Übersicht der Luftmesswerte (Datenblatt „Taskforce Burgenland - Luftmessungen", laut Dateiname Stand 07.07.2026), mit Anmerkungen. burgenland.at
- Langer, A. M., Constantopoulos, S. H., Nolan, R. P. & Moutsopoulos, H. M. (1987): Association of Metsovo lung and pleural mesothelioma with exposure to tremolite-containing whitewash. The Lancet 329(8539):965–967. doi.org/10.1016/S0140-6736(87)90305-9
- Lee, P. N. (2001): Relation between exposure to asbestos and smoking jointly and the risk of lung cancer. Occupational and Environmental Medicine 58(3):145–153. doi.org/10.1136/oem.58.3.145
- Luce, D., Bugel, I., Goldberg, P. et al. (2000): Environmental exposure to tremolite and respiratory cancer in New Caledonia: a case-control study. American Journal of Epidemiology 151(3):259–265. doi.org/10.1093/oxfordjournals.aje.a010201
- McCormack, V., Peto, J., Byrnes, G., Straif, K. & Boffetta, P. (2012): Estimating the asbestos-related lung cancer burden from mesothelioma mortality. British Journal of Cancer 106(3):575–584. doi.org/10.1038/bjc.2011.563
- McDonald, J. C. & McDonald, A. D. (1997): Chrysotile, tremolite and carcinogenicity. Annals of Occupational Hygiene 41(6):699–705. doi.org/10.1093/annhyg/41.6.699
- Ngamwong, Y., Tangamornsuksan, W., Lohitnavy, O. et al. (2015): Additive synergism between asbestos and smoking in lung cancer risk: a systematic review and meta-analysis. PLOS ONE 10(8):e0135798. doi.org/10.1371/journal.pone.0135798
- Pohlabeln, H., Wild, P., Schill, W. et al. (2002): Asbestos fibreyears and lung cancer: a two phase case-control study with expert exposure assessment. Occupational and Environmental Medicine 59(6):410–414. doi.org/10.1136/oem.59.6.410
- Robinson, B. W. S., Musk, A. W. & Lake, R. A. (2005): Malignant mesothelioma. The Lancet 366(9483):397–408. doi.org/10.1016/S0140-6736(05)67025-0
- Roggli, V. L., Vollmer, R. T., Butnor, K. J. & Sporn, T. A. (2002): Tremolite and mesothelioma. Annals of Occupational Hygiene 46(5):447–453. doi.org/10.1093/annhyg/mef056
- Stayner, L. T., Dankovic, D. A. & Lemen, R. A. (1996): Occupational exposure to chrysotile asbestos and cancer risk: a review of the amphibole hypothesis. American Journal of Public Health 86(2):179–186. doi.org/10.2105/AJPH.86.2.179
- Stayner, L., Smith, R., Bailer, J. et al. (1997): Exposure-response analysis of risk of respiratory disease associated with occupational exposure to chrysotile asbestos. Occupational and Environmental Medicine 54(9):646–652. doi.org/10.1136/oem.54.9.646
- TRGS 910 (2014): Technische Regeln für Gefahrstoffe 910 „Risikobezogenes Maßnahmenkonzept für Tätigkeiten mit krebserzeugenden Gefahrstoffen". Bundesanstalt für Arbeitsschutz und Arbeitsmedizin (BAuA), GMBl 2014, mit Aktualisierungen. baua.de
- Vogelzang, N. J., Rusthoven, J. J., Symanowski, J. et al. (2003): Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. Journal of Clinical Oncology 21(14):2636–2644. doi.org/10.1200/JCO.2003.11.136
- Wagner, J. C., Sleggs, C. A. & Marchand, P. (1960): Diffuse pleural mesothelioma and asbestos exposure in the North Western Cape Province. British Journal of Industrial Medicine 17(4):260–271. doi.org/10.1136/oem.17.4.260
- Wolff, H., Vehmas, T., Oksa, P., Rantanen, J. & Vainio, H. (2015): Asbestos, asbestosis, and cancer, the Helsinki criteria for diagnosis and attribution 2014: recommendations. Scandinavian Journal of Work, Environment & Health 41(1):5–15. doi.org/10.5271/sjweh.3462
Questions on the topic? → Contact